Shanghai Haohai Biological Technology released its semi-annual report: hyaluronic acid product revenue increased by over 50% year-on-year, while revenue from multiple product lines in ophthalmology decreased.
Regarding new products, Shanghai Haohai Biological Technology has successfully obtained approval for the world's first organic cross-linked hyaluronic acid product 'Haimei Yuebai' developed globally in July this year, while the Asia Vets cross-linked collagen product entered the registration and inspection stage in June. Due to the selected price decline in the quantity-based procurement of artificial crystalline lenses, sales revenue decreased year-on-year. As for the consumer market, it is showing signs of fatigue coupled with an increase in the number of competing products, resulting in a decline in revenue from corneal shaping lens business.
AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.
Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
2023 Interim Report | The next city is hard to find. How should Jiu'an Healthcare, which has 3 billion dollars in cash, spend money?
Invest
NASH testing works on a pay-per-use basis, and Furui shares surged 19% | Insight Research
The next 10 billion dollar market - NASH
2023 Interim Report | When CT Is No Longer a “Amulet”: What is Lianying Healthcare's MR Growth Space
Also watch This Morning